zomig instant-2,5 2,5 mg compr. disp.
grunenthal sa-nv - zolmitriptan 2,5 mg - comprimé dispersible - 2,5 mg - zolmitriptan 2.5 mg - zolmitriptan
zomig instant-5 5 mg compr. orodisp.
grunenthal sa-nv - zolmitriptan 5 mg - comprimé orodispersible - 5 mg - zolmitriptan 5 mg - zolmitriptan
zomig nasal-2,5 2.5 mg/dose sol. pulv. nas. flac. pulv.
grunenthal sa-nv - zolmitriptan 2,5 mg/0,1 ml - solution pour pulvérisation nasale - 2,5 mg/dose - zolmitriptan 2.5 mg/dose - zolmitriptan
zomig nasal-5 5 mg/dose sol. pulv. nas. flac. pulv.
grunenthal sa-nv - zolmitriptan 5 mg/0,1 ml - solution pour pulvérisation nasale - 5 mg/dose - zolmitriptan 5 mg/dose - zolmitriptan
zomig oral 2,5 2.5 mg compr. pellic.
grunenthal sa-nv - zolmitriptan 2,5 mg - comprimé pelliculé - 2,5 mg - zolmitriptan 2.5 mg - zolmitriptan
zomig oral 5 5 mg comp.
grunenthal sa-nv - zolmitriptan 5 mg - comprimé - 5 mg - zolmitriptan 5 mg - zolmitriptan
zomig nasal spray
astrazeneca limited - zolmitriptan 5mg - nasal spray solution - 5 mg - active: zolmitriptan 5mg excipient: citric acid dibasic sodium phosphate dihydrate purified water
zomig nasal spray
astrazeneca limited - zolmitriptan 50 mg/ml - nasal spray solution - 5 mg/dose - active: zolmitriptan 50 mg/ml excipient: citric acid dibasic sodium phosphate dihydrate purified water
zomig 2.5 mg
astrazeneca (israel) ltd - zolmitriptan - film coated tablets - zolmitriptan 2.5 mg - zolmitriptan - zolmitriptan - acute treatment of migraine with or without aura.
zomig- zolmitriptan tablet
dispensing solutions, inc. - zolmitriptan (unii: 2fs66th3yw) (zolmitriptan - unii:2fs66th3yw) - zolmitriptan 5 mg - zomig is indicated for the acute treatment of migraine with or without aura in adults. zomig should only be used where a clear diagnosis of migraine has been established. zomig is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications). safety and effectiveness of zomig have not been established for cluster headache, which is present in an older, predominantly male population. zomig should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including prinzmetal’s variant angina, or other significant underlying cardiovascular disease (see warnings and precautions). zomig should not be given to patients with cerebrovascular syndromes including (but not limited to) stroke of any type as well as transient ischemic attacks (see warnings